The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
SOCIETY: AGA By popular demand, this new session highlights the best late-breakers submitted to the IBD section and well as innovations in technology and new paradigms of care in IBD
SOCIETY: AGA This session highlights the best of the best observational studies in IBD for DDW 2024 and provides clinical relevant and novel insights across the age and clinical spectrum, including wound healing after C-section…
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…